Patent ID: 8084218

Claim:
A method for diagnosing a colon cancer by measuring an extent of β1,6 N-acetylglucosamine glycosylation and an expression level of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) protein related to tumorigenesis and metastasis, comprising: measuring an expression level of TIMP-1 protein in a colon, blood, or serum test sample isolated from a subject, wherein the expression level of TIMP-1 protein is measured using a labeled antibody against the TIMP-1 protein; measuring an extent of β1,6 N-acetylglucosamine glycosylation of the TIMP-1 protein in the test sample, wherein the extent of β1,6 N-acetylglucosamine glycosylation of the TIMP-1 protein is measured using labeled L4-PHA; and comparing the expression of the TIMP-1 protein and the extent of β1,6 N-acetylglucosamine glycosylation of the TIMP-1 protein between the test sample and a control sample, wherein an increase in the expression level of the TIMP-1 protein and the extent of β1,6 N-acetylglucosamine glycosylation of the TIMP-1 protein in the test sample relative to the control sample indicates presence of the colon cancer.